Absci is a drug and target discovery company. Co. develops an integrated drug creation platform by merging deep learning artificial intelligence (AI) and synthetic biology. The integrated drug creation platform enables target identification, and parallel discovery of biologics and with production cell lines by incorporating biodiversity, high-throughput single cell single cell assays, and deep learning AI models. Co. uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and Co. learns from the data it generates. Co.'s designs are AI-informed and its technology platform is scaffold-agnostic. The ABSI stock yearly return is shown above.
The yearly return on the ABSI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ABSI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|